Peregrine Pharmaceuticals has received Fast Track designation from the FDA for immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer (NSCLC). The company recently initiated SUNRISE, a pivotal Phase III trial comparing bavituximab plus the chemotherapy docetaxel against placebo plus docetaxel in this indication. Fast Track status is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-thre...